1. Investigational cannabinoids in seizure disorders, what have we learned thus far?
- Author
-
Slobodan M. Jankovic, Ziyad Tantoush, Marko Folić, Milan Radovanovic, Dejana Ružić Zečević, and Goran Babic
- Subjects
0301 basic medicine ,Drug Resistant Epilepsy ,Cannabidivarin ,medicine.medical_treatment ,MEDLINE ,Epilepsies, Myoclonic ,Bioinformatics ,03 medical and health sciences ,Epilepsy ,0302 clinical medicine ,Dravet syndrome ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Pharmacology ,Cannabinoids ,Lennox Gastaut Syndrome ,business.industry ,Drugs, Investigational ,General Medicine ,medicine.disease ,Clinical trial ,030104 developmental biology ,Anticonvulsant ,Drug Design ,Anticonvulsants ,business ,Cannabidiol ,030217 neurology & neurosurgery ,medicine.drug ,Lennox–Gastaut syndrome - Abstract
The anticonvulsant activity of cannabinoids attracted much attention in the last decade. Cannabinoids that are currently investigated with the intention of making them drugs for the treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin, and Δ9-tetrahydrocannabinolic acid.In this review, the authors look at the results of preclinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR, and SCINDEX databases.Preclinical studies confirmed anticonvulsant activity of cannabidiol and cannabidivarin in a variety of epilepsy models. While the results of clinical trials with cannabidivarin are still awaited, cannabidiol showed clear therapeutic benefit and good safety in patients with therapy-resistant seizures associated with Dravet syndrome and in patients with Lennox-Gastaut syndrome who have drop seizures. However, the full therapeutic potential of cannabinoids in treatment-resistant epilepsy needs to be investigated in the near future.
- Published
- 2018
- Full Text
- View/download PDF